Aromatase inhibitors (AIs) are associated with hypoactive sexual desire disorder (HSDD) and fecal incontinence in breast cancer survivors ten years after diagnosis, according to a recent Journal of Sexual Medicine study.
FDA Panel Conditionally Recommends Flibanserin Approval
On June 4, an advisory panel to the U.S. Food and Drug Administration (FDA) voted 18-6 in favor of recommending the approval of flibanserin for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women in the United States.
Flibanserin, HSDD, and the BEGONIA Trial
Results of a recent drug trial suggest that premenopausal women with hypoactive sexual desire disorder (HSDD) may benefit from a daily dose of flibanserin, a medication designed to improve sexual desire.